TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS TURBO UNLIMITED LONG- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - VERTEX PHARMACEUTICALS Stock
Certificat
DE000SF7XYC5
| Market Closed - Deutsche Boerse AG 15:38:51 2024-05-24 EDT | ||
| 23.4 EUR | +1.96% |
|
| Current month | +28.78% | ||
| 1 month | +24.80% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-24 | 23.4 | +1.96% |
| 24-05-23 | 22.95 | +1.59% |
| 24-05-22 | 22.59 | +2.78% |
| 24-05-21 | 21.98 | -2.57% |
| 24-05-20 | 22.56 | +1.12% |
Delayed Quote Deutsche Boerse AG
Last update May 24, 2024 at 03:38 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SF7XYC |
| ISIN | DE000SF7XYC5 |
| Date issued | 2021-08-19 |
| Strike | 204.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.53 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.4 € |
|---|---|
| Lowest since issue | 0.78 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
457
USD
Average target price
462.8
USD
Spread / Average Target
+1.28%
- Stock Market
- Certificates
- Certificat
